Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos Gomez-Roca

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
European Journal of Cancer (Oxford, England : 1990)|November 8, 2020
Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumourPhilippe A Cassier, Antoine Italiano, Carlos Gomez-Roca, et al.
Cancers|July 14, 2023
Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib CohortOlivier Trédan, Maud Toulmonde, Christophe Le Tourneau, et al.
Nature Medicine|April 8, 2025
Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trialOlivier Trédan, Damien Pouessel, Nicolas Penel, et al.
Oncotarget|August 11, 2016
First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumorsC Willemien Menke-van der Houven van Oordt, Carlos Gomez-Roca, Carla van Herpen, et al.
European Journal of Cancer (Oxford, England : 1990)|April 25, 2026
A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumoursMarie Robert, Nuria Kotecki, Carlos Gomez-Roca, et al.
Journal for Immunotherapy of Cancer|October 24, 2020
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patientsJean-Pascal Machiels, Carlos Gomez-Roca, Jean-Marie Michot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2023
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)Alexandra Drakaki, Thomas Powles, Aristotelis Bamias, et al.
BMC Cancer|February 23, 2019
Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imagingAnne Laprie, Soléakhéna Ken, Thomas Filleron, et al.
Nature|May 31, 2023
In situ tumour arrays reveal early environmental control of cancer immunityGuadalupe Ortiz-Muñoz, Markus Brown, Catherine B Carbone, et al.
Cancer Cell|June 6, 2014
Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapyCarola H Ries, Michael A Cannarile, Sabine Hoves, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
European Journal of Cancer (Oxford, England : 1990)|November 8, 2020
Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumourPhilippe A Cassier, Antoine Italiano, Carlos Gomez-Roca, et al.
Cancers|July 14, 2023
Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib CohortOlivier Trédan, Maud Toulmonde, Christophe Le Tourneau, et al.
Nature Medicine|April 8, 2025
Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trialOlivier Trédan, Damien Pouessel, Nicolas Penel, et al.
Oncotarget|August 11, 2016
First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumorsC Willemien Menke-van der Houven van Oordt, Carlos Gomez-Roca, Carla van Herpen, et al.
European Journal of Cancer (Oxford, England : 1990)|April 25, 2026
A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumoursMarie Robert, Nuria Kotecki, Carlos Gomez-Roca, et al.
Journal for Immunotherapy of Cancer|October 24, 2020
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patientsJean-Pascal Machiels, Carlos Gomez-Roca, Jean-Marie Michot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2023
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)Alexandra Drakaki, Thomas Powles, Aristotelis Bamias, et al.
BMC Cancer|February 23, 2019
Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imagingAnne Laprie, Soléakhéna Ken, Thomas Filleron, et al.
Nature|May 31, 2023
In situ tumour arrays reveal early environmental control of cancer immunityGuadalupe Ortiz-Muñoz, Markus Brown, Catherine B Carbone, et al.
Cancer Cell|June 6, 2014
Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapyCarola H Ries, Michael A Cannarile, Sabine Hoves, et al.
Pageof 8